Lockheed Martin Corporation vs Smith & Nephew plc — how do they compare? Lockheed Martin Corporation trades at $597 (market cap $139.20B), while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Lockheed Martin Corporation is far larger — about 11.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| LMT | SNN | |
|---|---|---|
Market Cap | $139.20B | $12.50B |
Sector | Industrials | Health |
52-Week High | $676.70 | $38.70 |
52-Week Low | $431.56 | $28.73 |
Enterprise Value | $155.95B | $15.53B |
Dividend Yield | 2.29% | 2.64% |
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $587.95, up 0.9% with bullish technical signals and strong institutional support. The company reported mixed Q2 2026 earnings with a beat on EPS ($7.94 vs. $7.22 expected) but maintains a record $230B backlog. Valuation metrics show a P/E of 21.68 and ROE of 89.16%, though recent quarters saw earnings misses. Technical indicators suggest bullish momentum with key resistance at $592.
Outlook remains positive driven by defense contract wins and production expansion, but risks include execution on massive backlog and debt levels. Analyst consensus is bullish with $608 price target representing 3.4% upside. The stock offers stability through dividends ($3.45 quarterly) amid geopolitical demand for defense systems.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →